Chemo-Pharma [CPL] vs Equippp Social [EQUIPPP] Detailed Stock Comparison
Chemo-Pharma
BSE
Loading...
Equippp Social
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Chemo-Pharma wins in 16 metrics, Equippp Social wins in 3 metrics, with 0 ties. Chemo-Pharma appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Chemo-Pharma | Equippp Social | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 12.17 | 166.36 | Chemo-Pharma |
| Price-to-Book Ratio | 2.56 | 22.07 | Chemo-Pharma |
| Debt-to-Equity Ratio | 44.70 | 66.89 | Chemo-Pharma |
| PEG Ratio | 0.62 | -0.67 | Equippp Social |
| EV/EBITDA | 13.74 | 84.48 | Chemo-Pharma |
| Profit Margin (TTM) | 11.11% | 4.44% | Chemo-Pharma |
| Operating Margin (TTM) | 9.62% | 3.05% | Chemo-Pharma |
| EBITDA Margin (TTM) | 9.62% | 3.05% | Chemo-Pharma |
| Return on Equity | 20.97% | 4.40% | Chemo-Pharma |
| Return on Assets (TTM) | 11.26% | 2.16% | Chemo-Pharma |
| Free Cash Flow (TTM) | $41.66M | $-19.15M | Chemo-Pharma |
| 1-Year Return | -14.20% | -20.70% | Chemo-Pharma |
| Price-to-Sales Ratio (TTM) | 1.42 | 11.79 | Chemo-Pharma |
| Enterprise Value | $4.61B | $1.99B | Chemo-Pharma |
| EV/Revenue Ratio | 1.58 | 12.29 | Chemo-Pharma |
| Gross Profit Margin (TTM) | 29.30% | 99.85% | Equippp Social |
| Revenue per Share (TTM) | $51 | $1 | Chemo-Pharma |
| Earnings per Share (Diluted) | $5.66 | $0.11 | Chemo-Pharma |
| Beta (Stock Volatility) | 0.22 | -0.98 | Equippp Social |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Chemo-Pharma vs Equippp Social Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Chemo-Pharma | -0.47% | -1.88% | -7.83% | -14.89% | -23.12% | -41.76% |
| Equippp Social | -0.80% | 2.78% | -2.68% | -7.55% | -16.78% | -29.15% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Chemo-Pharma | -14.20% | 314.25% | 117.43% | 728.00% | 1,222.85% | 1,222.85% |
| Equippp Social | -20.70% | -66.64% | 208.33% | -56.98% | -87.06% | -87.06% |
Performance & Financial Health Analysis: Chemo-Pharma vs Equippp Social
| Metric | CPL | EQUIPPP |
|---|---|---|
| Market Information | ||
| Market Cap | ₹4.13B | ₹1.91B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 37,361 | 16,109 |
| 90 Day Avg. Volume | 36,863 | 20,266 |
| Last Close | ₹67.73 | ₹18.50 |
| 52 Week Range | ₹61.40 - ₹128.00 | ₹16.26 - ₹30.10 |
| % from 52W High | -47.09% | -38.54% |
| All-Time High | ₹128.00 (Jan 06, 2025) | ₹181.15 (Oct 18, 2021) |
| % from All-Time High | -47.09% | -89.79% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | 20.23% |
| Quarterly Earnings Growth | 0.34% | 20.19% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | 0.04% |
| Operating Margin (TTM) | 0.10% | 0.03% |
| Return on Equity (TTM) | 0.21% | 0.04% |
| Debt to Equity (MRQ) | 44.70 | 66.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹26.86 | ₹0.83 |
| Cash per Share (MRQ) | ₹1.01 | ₹0.48 |
| Operating Cash Flow (TTM) | ₹277.99M | ₹-13,950,000 |
| Levered Free Cash Flow (TTM) | ₹313.23M | ₹5.82M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Chemo-Pharma vs Equippp Social
| Metric | CPL | EQUIPPP |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 12.17 | 166.36 |
| Forward P/E | N/A | N/A |
| PEG Ratio | 0.62 | -0.67 |
| Price to Sales (TTM) | 1.42 | 11.79 |
| Price to Book (MRQ) | 2.56 | 22.07 |
| Market Capitalization | ||
| Market Capitalization | ₹4.13B | ₹1.91B |
| Enterprise Value | ₹4.61B | ₹1.99B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.58 | 12.29 |
| Enterprise to EBITDA | 13.74 | 84.48 |
| Risk & Other Metrics | ||
| Beta | 0.22 | -0.98 |
| Book Value per Share (MRQ) | ₹26.86 | ₹0.83 |
Financial Statements Comparison: Chemo-Pharma vs Equippp Social
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CPL | EQUIPPP |
|---|---|---|
| Revenue/Sales | ₹697.42M | ₹57.09M |
| Cost of Goods Sold | ₹493.08M | ₹0 |
| Gross Profit | ₹204.34M | ₹57.09M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹67.12M | ₹22.66M |
| EBITDA | ₹79.31M | ₹23.22M |
| Pre-Tax Income | ₹55.13M | ₹21.10M |
| Income Tax | ₹12.13M | ₹5.45M |
| Net Income (Profit) | ₹42.99M | ₹15.66M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CPL | EQUIPPP |
|---|---|---|
| Cash & Equivalents | ₹12.05M | ₹49.58M |
| Total Current Assets | ₹2.51B | ₹172.85M |
| Total Current Liabilities | ₹1.17B | ₹43.95M |
| Long-Term Debt | ₹109.50M | ₹88.51M |
| Total Shareholders Equity | ₹1.49B | ₹132.33M |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹144.04M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CPL | EQUIPPP |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CPL | EQUIPPP |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 37,361 | 16,109 |
| Average Daily Volume (90 Day) | 36,863 | 20,266 |
| Shares Outstanding | 57.55M | 103.10M |
| Float Shares | 17.06M | 13.20M |
| % Held by Insiders | 0.70% | 0.87% |
| % Held by Institutions | 0.00% | 0.00% |
Dividend Analysis & Yield Comparison: Chemo-Pharma vs Equippp Social
| Metric | CPL | EQUIPPP |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | ₹0.00 | ₹0.00 |
| Ex-Dividend Date | N/A | N/A |